WO2002055087A1 - Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain - Google Patents

Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain Download PDF

Info

Publication number
WO2002055087A1
WO2002055087A1 PCT/IB2002/000081 IB0200081W WO02055087A1 WO 2002055087 A1 WO2002055087 A1 WO 2002055087A1 IB 0200081 W IB0200081 W IB 0200081W WO 02055087 A1 WO02055087 A1 WO 02055087A1
Authority
WO
WIPO (PCT)
Prior art keywords
triterpenes
triterpene
group
dihydroparkeol
dihydrolupeol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/000081
Other languages
English (en)
French (fr)
Other versions
WO2002055087B1 (en
Inventor
Morten Sloth Weidner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BSP Pharma AS
Original Assignee
BSP Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2434670A priority Critical patent/CA2434670C/en
Priority to AU2002225259A priority patent/AU2002225259B2/en
Priority to NZ526969A priority patent/NZ526969A/en
Priority to US10/466,093 priority patent/US20040054004A1/en
Priority to DE60214509T priority patent/DE60214509T2/de
Priority to JP2002555821A priority patent/JP2004520343A/ja
Priority to CN028036794A priority patent/CN1520300B/zh
Priority to DK02715601T priority patent/DK1349553T3/da
Priority to EP02715601A priority patent/EP1349553B1/en
Application filed by BSP Pharma AS filed Critical BSP Pharma AS
Publication of WO2002055087A1 publication Critical patent/WO2002055087A1/en
Publication of WO2002055087B1 publication Critical patent/WO2002055087B1/en
Anticipated expiration legal-status Critical
Priority to CY20061101714T priority patent/CY1106270T1/el
Priority to US12/572,785 priority patent/US20100029600A1/en
Priority to US12/572,789 priority patent/US20100087531A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/IB2002/000081 2001-01-12 2002-01-14 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain Ceased WO2002055087A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP02715601A EP1349553B1 (en) 2001-01-12 2002-01-14 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
NZ526969A NZ526969A (en) 2001-01-12 2002-01-14 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
US10/466,093 US20040054004A1 (en) 2001-01-12 2002-01-14 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, in flammation, hypersensitivity or pain
DE60214509T DE60214509T2 (de) 2001-01-12 2002-01-14 Dihydrotriterpene bei der Behandlung von viralen Infektionen, Herz-Kreislauf-Erkrankungen, Entzündungen, Üüberempfindlichkeit oder Schmerzen
JP2002555821A JP2004520343A (ja) 2001-01-12 2002-01-14 ウイルス感染、心血管疾患、炎症、過敏症、または痛みの処置におけるジヒドロトリテルペン
CN028036794A CN1520300B (zh) 2001-01-12 2002-01-14 用于治疗病毒感染、心血管病、炎症、超敏反应或疼痛的二氢三萜烯
DK02715601T DK1349553T3 (da) 2001-01-12 2002-01-14 Dihydro-triterpener til behandling af virusinfektioner, kardiovaskulær sygdom, inflammation, overfölsomhed eller smerte
CA2434670A CA2434670C (en) 2001-01-12 2002-01-14 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
AU2002225259A AU2002225259B2 (en) 2001-01-12 2002-01-14 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
CY20061101714T CY1106270T1 (el) 2001-01-12 2006-11-28 Διυδρο-τριτepπενια στην αντιμετωπιση ιογενων μολυνσεων, καρδιαγγειακης νοσου, φλεγμονης, υπepευαισθησιας ή πονου
US12/572,785 US20100029600A1 (en) 2001-01-12 2009-10-02 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
US12/572,789 US20100087531A1 (en) 2001-01-12 2009-10-02 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200100049 2001-01-12
DKPA200100049 2001-01-12
US26116801P 2001-01-16 2001-01-16
US60/261,168 2001-01-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/572,785 Continuation US20100029600A1 (en) 2001-01-12 2009-10-02 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
US12/572,789 Division US20100087531A1 (en) 2001-01-12 2009-10-02 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain

Publications (2)

Publication Number Publication Date
WO2002055087A1 true WO2002055087A1 (en) 2002-07-18
WO2002055087B1 WO2002055087B1 (en) 2002-12-27

Family

ID=26068943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/000081 Ceased WO2002055087A1 (en) 2001-01-12 2002-01-14 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain

Country Status (12)

Country Link
EP (1) EP1349553B1 (enExample)
JP (1) JP2004520343A (enExample)
CN (1) CN1520300B (enExample)
AT (1) ATE338556T1 (enExample)
AU (1) AU2002225259B2 (enExample)
CA (1) CA2434670C (enExample)
CY (1) CY1106270T1 (enExample)
DE (1) DE60214509T2 (enExample)
DK (1) DK1349553T3 (enExample)
ES (1) ES2272689T3 (enExample)
NZ (1) NZ526969A (enExample)
WO (1) WO2002055087A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1424073A1 (en) * 2002-11-27 2004-06-02 Loders Croklaan B.V. Anti diarrhoea compositions
WO2005077377A1 (en) * 2004-02-06 2005-08-25 Regents Of The University Of Minnesota Compositions that include a triterpene and a carrier
JP2006151902A (ja) * 2004-11-30 2006-06-15 Akita Prefecture 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
US7070815B2 (en) 2002-11-27 2006-07-04 Loders Croklaan Usa Llc Anti diarrhoea compositions
CN104107179A (zh) * 2014-06-27 2014-10-22 南京广康协生物医药技术有限公司 闭花木酮Cleistanone的二乙胺衍生物在制备抗急性痛风药物中的应用
KR20160084915A (ko) * 2015-01-06 2016-07-15 목포대학교산학협력단 동백나무 추출물을 유효성분으로 포함하는 심혈관계 질환의 예방 또는 치료용 조성물
WO2018051296A3 (en) * 2016-09-19 2018-04-26 Codex V Srl Non—saponifiable compounds of natural lipids for use in the treatment of rheumatic pathologies

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007108042A1 (ja) * 2006-03-15 2009-07-30 株式会社トロピカルテクノセンター 抗炎症剤
JP5428000B2 (ja) * 2007-06-27 2014-02-26 株式会社スカイライト・バイオテック ルペオール含有医薬組成物、食品及び飼料
CN102499925B (zh) * 2011-10-21 2015-11-11 上海中医药大学 一种中性粒细胞弹性蛋白酶抑制剂
CN106265684A (zh) * 2016-08-11 2017-01-04 江苏康缘药业股份有限公司 乙酰羽扇豆醇酯的应用
WO2018082034A1 (en) * 2016-11-04 2018-05-11 Trineo Biotechnology Co., Ltd Uses of triterpenoid mixture for treating multiple sclerosis
CN113993533A (zh) * 2019-05-22 2022-01-28 人类科学有限公司 包含山茶树提取物作为有效成分的用于预防及治疗病毒感染的药物组合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB932662A (en) * 1960-04-13 1963-07-31 Laroche Navarron Lab Therapeutic compositions comprising butyrospermol
US4748161A (en) * 1984-06-04 1988-05-31 Amano Pharmaceutical Co., Ltd. Triterpenyl esters of organic acids and hypolipidemic agents composed of them
JPH05186326A (ja) * 1992-01-10 1993-07-27 Sunstar Inc 皮膚化粧料
WO1995035103A1 (en) * 1994-06-20 1995-12-28 Kurt Berg A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof
WO1998032443A1 (de) * 1997-01-24 1998-07-30 Marigen S.A. Ultramikroemulsionen aus spontan dispergierbaren konzentraten enthaltend antitumoral, antiviral und antiparasitär wirksame ester von pentacyclischen triterpenen
FR2770400A1 (fr) * 1997-10-30 1999-05-07 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir de la fleur de l'arbre a karite ou butyrospermum parkii kotschy
WO2001003712A1 (en) * 1999-07-09 2001-01-18 Astion Development Aps Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB932662A (en) * 1960-04-13 1963-07-31 Laroche Navarron Lab Therapeutic compositions comprising butyrospermol
US4748161A (en) * 1984-06-04 1988-05-31 Amano Pharmaceutical Co., Ltd. Triterpenyl esters of organic acids and hypolipidemic agents composed of them
US4748161B1 (enExample) * 1984-06-04 1991-10-15 Amano Pharma Co Ltd
JPH05186326A (ja) * 1992-01-10 1993-07-27 Sunstar Inc 皮膚化粧料
WO1995035103A1 (en) * 1994-06-20 1995-12-28 Kurt Berg A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof
WO1998032443A1 (de) * 1997-01-24 1998-07-30 Marigen S.A. Ultramikroemulsionen aus spontan dispergierbaren konzentraten enthaltend antitumoral, antiviral und antiparasitär wirksame ester von pentacyclischen triterpenen
FR2770400A1 (fr) * 1997-10-30 1999-05-07 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir de la fleur de l'arbre a karite ou butyrospermum parkii kotschy
WO2001003712A1 (en) * 1999-07-09 2001-01-18 Astion Development Aps Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BUDZIKIEWICZ H ET AL: "Mass spectrometry in structural and stereochemical problems. XXXII. Pentacyclic triterpenes.", JOURNAL AMERICAN SOC., vol. 85, 1963, pages 3688 - 3699, XP002902437 *
DATABASE STN INTERNATIONAL [online] file caplus; DEL CARMEN RECIO M ET AL: "Structural requirements for the anti-inflammatory activity of natural triterpenoids.", XP002902439, retrieved from CAPLUS accession no. 1995:544934 Database accession no. 122:281461 *
DATABASE WPI Section Ch Week 199334, Derwent World Patents Index; Class D21, AN 1993-269741, XP002902440 *
DE DECKERE E A M ET AL: "Minor constituents of rice bran oil as functional foods.", NUTRITION REVIEWS, vol. 54, no. 11, November 1996 (1996-11-01), pages s120 - s126, XP002902441 *
PLANTA MED., vol. 61, no. 2, 1995, pages 182 - 185 *
TOSHIHIRO AKIHISA ET AL: "Inhibitory effects of triterpenoids and sterols on human immunodeficiency Virus-1 reverse transcriptase.", LIPIDS, vol. 36, no. 5, May 2001 (2001-05-01), pages 507 - 512, XP002902442 *
TOSHIHIRO AKIHISA ET AL: "Triterpene alcohols from camellia and sasanqua oils and their anti-inflammatory effects.", CHEM. PHARM. BULL., vol. 45, no. 12, 1997, pages 2016 - 2023, XP002902438 *
TOSHIHIRO ITOH ET AL: "Sterols,methylsterols, and triterpene alcohols in three THEACEAE and some other vegetable oils.", LIPIDS, vol. 9, no. 3, 1974, pages 173 - 184, XP002902463 *
YASUKAWA K ET AL: "SOME LUPANE-TYPE TRITERPENES INHIBIT TUMOR PROMOTION BY 12-O-TETRADECANOYLPHORBOL-13-ACETATE IN TWO-STAGE CARCINOGENESIS IN MOUSE SKIN", PHYTOMEDICINE, GUSTAV FISCHER VERLAG, STUTTGART, DE, vol. 4, 1995, pages 309 - 313, XP000610925, ISSN: 0944-7113 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1424073A1 (en) * 2002-11-27 2004-06-02 Loders Croklaan B.V. Anti diarrhoea compositions
US7070815B2 (en) 2002-11-27 2006-07-04 Loders Croklaan Usa Llc Anti diarrhoea compositions
WO2005077377A1 (en) * 2004-02-06 2005-08-25 Regents Of The University Of Minnesota Compositions that include a triterpene and a carrier
JP2006151902A (ja) * 2004-11-30 2006-06-15 Akita Prefecture 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
CN104107179A (zh) * 2014-06-27 2014-10-22 南京广康协生物医药技术有限公司 闭花木酮Cleistanone的二乙胺衍生物在制备抗急性痛风药物中的应用
KR20160084915A (ko) * 2015-01-06 2016-07-15 목포대학교산학협력단 동백나무 추출물을 유효성분으로 포함하는 심혈관계 질환의 예방 또는 치료용 조성물
KR101672431B1 (ko) 2015-01-06 2016-11-04 목포대학교산학협력단 동백나무 추출물을 유효성분으로 포함하는 심혈관계 질환의 예방 또는 치료용 조성물
WO2018051296A3 (en) * 2016-09-19 2018-04-26 Codex V Srl Non—saponifiable compounds of natural lipids for use in the treatment of rheumatic pathologies

Also Published As

Publication number Publication date
DE60214509D1 (de) 2006-10-19
EP1349553B1 (en) 2006-09-06
CY1106270T1 (el) 2011-10-12
CN1520300B (zh) 2010-10-06
DE60214509T2 (de) 2007-05-31
EP1349553A1 (en) 2003-10-08
JP2004520343A (ja) 2004-07-08
NZ526969A (en) 2005-05-27
WO2002055087B1 (en) 2002-12-27
CA2434670A1 (en) 2002-07-18
ES2272689T3 (es) 2007-05-01
DK1349553T3 (da) 2007-01-08
AU2002225259B2 (en) 2006-02-02
ATE338556T1 (de) 2006-09-15
CN1520300A (zh) 2004-08-11
CA2434670C (en) 2010-05-11

Similar Documents

Publication Publication Date Title
CA2434670C (en) Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
Nawawi et al. Inhibitory effects of Indonesian medicinal plants on the infection of herpes simplex virus type 1
Zhang et al. Chemical properties, mode of action, and in vivo anti-herpes activities of a lignin–carbohydrate complex from Prunella vulgaris
AU2002225259A1 (en) Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
US8853261B2 (en) Nutraceutical composition from Garcinia mangostana
NZ517077A (en) Extract of Butyrospermum parkii (Karite tree) comprising at least 5% of a Butyrospermum-triterpene fraction for topical and systemic treatment of hypersensitivity disorders
US6264928B1 (en) Use of shogaols and gingerols for preparing deodorant compositions
CA2355776C (en) Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
US20100029600A1 (en) Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
CN101890038A (zh) 女贞苷、野漆树苷、金丝桃苷组合物及其制备药物用途
KR101663576B1 (ko) 플로레틴 술폰산염 및 이를 포함하는 피부 상태 개선용 조성물
EP4512408A1 (en) Composition, for preventing, ameliorating, or treating coronavirus infections, comprising herbal medicine extract as active ingredient
JP4185996B2 (ja) 抗インフルエンザウイルス剤
RU2380100C1 (ru) Средство для профилактики и лечения гриппа а и в
JP2006174844A (ja) ステビオール配糖体含有飲食品
JP4300409B2 (ja) クロロゲン酸エステル誘導体を用いた抗インフルエンザウイルス剤
WO2023249393A1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
CN114377111B (zh) 一种化痰止咳的药物组合物
JP2008517999A (ja) 呼吸器疾患の予防および治療に有用な苦参抽出物
Atta et al. Anti-inflammatory, antipyretic and antioxidant effect of some medicinal plant extracts
JP2006213726A (ja) ステビオール配糖体含有抗アレルギー剤
KR20240059128A (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
EP4205754A1 (en) Antiviral plant extract composition and method for preparing such composition
WO2022249952A1 (ja) 抗ウイルス剤
CN115803040A (zh) 用于处理covid-19和相关病症的组合物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

B Later publication of amended claims
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002715601

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002555821

Country of ref document: JP

Ref document number: 526969

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2434670

Country of ref document: CA

Ref document number: 028036794

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002225259

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 01265/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 10466093

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002715601

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 526969

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526969

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002225259

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2002715601

Country of ref document: EP